CBER Biologics Efficacy and Safety Sentinel (BEST) Program #2

Development of New and Innovative Methods for Automated Reporting for CBER-Regulated Biological Products

Alan E Williams, Ph.D. (on behalf of IQVIA and the BEST-2 Team)
Associate Director, Regulatory Affairs, CBER OBE
10/12/2018
Typical Biologics Product Approval Lifecycle

Clinical Investigational Plan

- **IND**: Investigational New Drug Application
- **BLA**: Biologics License Application

### Phase 1
- Safety

### Phase 2
- Safety
- Dose-ranging

### Phase 3
- Safety
- Efficacy

**BLA Data to support approval**

- Post-market studies (Phase 4)

- Passive Surveillance

- Active Surveillance
  (a form of real world evidence)
BEST #2 – Two Major Program Goals: Regulatory Perspective

I. Develop Infrastructure to improve the quality (accuracy and predictive value) of active post-market (PM) surveillance beyond what is available solely from ”big data” resources based on billing codes. (FDAAA 2207)
   1. Exposures
   2. Outcomes
   3. Initial emphasis on blood transfusion (hemovigilance)*

* Blood components are established products. Pre-market review is based on adequacy of manufacturing procedures, not efficacy)
BEST #2 – Program Goals: Regulatory Perspective

II. Increase the efficiency (reduce the burden) of PM surveillance reporting

PM e-reporting of product adverse events (AE) to FDA by manufacturers now required for most FDA-regulated products (passive); MEDWatch/FAERS/VAERS
- Many reports, variable quality

PM Reporting not required for blood transfusion at this time.
- Voluntary reporting to FDA essentially non-existent
- US hemovigilance (public and private) very challenging (no national healthcare system; poor data interoperability)
- Limited resources for hemovigilance at institutional level
- Adverse events are rare and have diagnostic complexity
Enhanced exposure and Outcome (Computable Phenotype) Development

- Outcome and Diagnostic codes alone (claims, EHR)
- Constellations of available structured data (enhanced claims, EHR)
- Computable phenotypes - available structured data + data mined from clinical and nursing notes, radiology reports, non-structured labs
- Case validation by clinical review of charts (semi-automated)
1. Improved sensitivity and granularity of transfusion exposures compared to claims data alone

*Lead: Columbia University*
BEST2 - Workstream 2/5

Iterative NLP-based development of computable phenotypes (CP) reflecting: **Enhanced characterization of Post-transfusion Transfusion-Associated Circulatory Overload (TACO)**

*Lead: Stanford University*
BEST2 - Workstream 3/5

Iterative NLP-based development of computable phenotypes (CP) reflecting: Post-transfusion Sepsis (PTS)

Regenstrief Institute
BEST2 - Workstream 4/5

Infrastructure to support interoperability within BEST (and potentially more broadly) through harmonized use of CLARITY NLP platform to support more efficient iterative NLP studies

Lead: Georgia Tech Research Institute (GTRI), Columbia University
BEST2 - Workstream 5/5

Building infrastructure to support *nationwide* scale-up of CP-based case identification and automated report generation

*Lead: Georgia Tech Research Institute*
Adverse Event Surveillance OHDSI Platform (AESOP)
BEST-2 Future Challenges

• Time stamps derived from EHR for events: hour/minute/(second?)

• Iterative CP development processes are of high value, but can efficiency be improved? (CBER regulates many unique products with unique AE)

• Collaboration with EHR vendors, HL7 FHIR to support eventual scale-up
Acknowledgements

Columbia
George Hripcsak
Karthik Natarajan
Chao Pang
Thomas Falconer

Georgia Tech
Jon Duke
Richard Boyd
Charity Hilton
Myung Choi
Michael Riley
Trey Schneider
Trina Paden
Marla Gorges

UCLA
Marc Suchard

IQVIA
Christian Reich
Michael Bruhn
Nandini Selvam
Matthew Stagg
Nerissa Williams
Paul Kodack

Stanford
Deepa Balraj
Juan Banda
Saurabh Gombar
Nigam Shah
Somalee Datta
Jim Singer

Regenstrief
Paul Biondich
Dan Hood
Jarrah Hamer
John Price
Suranga
Kasthurirathne
Andrew Martin
Chen Wen

CBER FDA
Steven Anderson
Barbee Whitaker
Emily Storch
Darren Jansen
Hussein Ezzeldin
Angelica Jones
Rich Forshee
Alan Williams
CBER Sentinel
Central Team